National Health (Weighted average disclosed price - supplementary disclosure cycle A) Determination 2013 (No. PB 24 of 2013)

Link to law: https://www.comlaw.gov.au/Details/F2013L00688

 
PB 24 of 2013
National Health (Weighted average disclosed price – supplementary disclosure cycle A) Determination 2013
National Health Act 1953
I, ADRIANA PLATONA, First Assistant Secretary (Acting), Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this determination under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the National Health Act 1953.
Dated          22 April 2013
 
 
 
 
 
 
 
 
 
ADRIANA PLATONA
 
First Assistant Secretary (Acting)
Pharmaceutical Benefits Division
Department of Health and Ageing
 
1              Name of Determination
       (1)     This Determination is the National Health (Weighted average disclosed price –supplementary disclosure cycle A) Determination 2013.
       (2)     This Determination may also be cited as PB 24 of 2013.
2              Commencement
                This Determination commences on the day after it is registered.
3                   Definitions
In this Determination:
 
Act means the National Health Act 1953.
 
adjusted approved ex-manufacturer price has the same meaning as in subsection 99ADB(1) of the Act.
 
supplementary disclosure cycle A has the same meaning as in regulation 37EB(2)(c) of the National Health (Pharmaceutical Benefits) Regulations 1960.
 
unadjusted price reduction has the same meaning as in subsection 99ADB(1) of the Act. 
                weighted average disclosed price has the same meaning as in subsection 99ADB(1) of the Act.
 
 
4                   Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is at least 10%
 
For subsection 99ADB(4) of the Act, the weighted average disclosed price specified in column 3 of an item in Schedule 1 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 1.
 
 
5                   Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is less than 10%
 
For subsection 99ADB(4) of the Act, the weighted average disclosed price specified in column 3 of an item in Schedule 2 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 2.
 
 
6                   Adjusted approved ex-manufacturer price for brands of pharmaceutical items – unadjusted price reduction is at least 10%
 
For paragraph 99ADB(4) of the Act, the adjusted approved ex-manufacturer price for a brand of pharmaceutical item specified in column 2 of Schedule 1 is an amount equal to the amount of the weighted average disclosed price of that brand of pharmaceutical item determined under section 4 of this instrument.
 
 
7                   Reduction Day
 
For paragraph 99ADH(1)(aa) of the Act, a brand of pharmaceutical item in a supplementary disclosure cycle A with a data collection period ending at the end of
31 January 2013 which is mentioned in Schedule 1 or 2 has a reduction day of
1 August 2013.
 
Schedule 1            
Brands of pharmaceutical items – unadjusted price reduction is at least 10%
 
Column 1
Column 2
Column 3

Item
Brand of Pharmaceutical Item
Weighted average disclosed price

 
Drug
Form
Manner of administration
Brand
 

1
Dexamethasone
Injection containing dexamethasone sodium phosphate equivalent to 4 mg dexamethasone phosphate in 1 mL
Injection
Dexmethsone
6.77

2
Dexamethasone
Injection containing dexamethasone sodium phosphate equivalent to 4 mg dexamethasone phosphate in 1 mL
Injection
Hospira Pty Limited
6.77

3
Dexamethasone
Injection containing dexamethasone sodium phosphate equivalent to 8 mg dexamethasone phosphate in 2 mL
Injection
Dexmethsone
12.3

4
Dexamethasone
Injection containing dexamethasone sodium phosphate equivalent to 8 mg dexamethasone phosphate in 2 mL
Injection
Hospira Pty Limited
12.3

5
Temozolomide
Capsule 100 mg
Oral
Orion Temozolomide
455.17

6
Temozolomide
Capsule 100 mg
Oral
Temodal
455.17

7
Temozolomide
Capsule 100 mg
Oral
Temizole 100
455.17

8
Temozolomide
Capsule 100 mg
Oral
Astromide
455.17

9
Temozolomide
Capsule 140 mg
Oral
Astromide
627.72

10
Temozolomide
Capsule 140 mg
Oral
Orion Temozolomide
627.72

11
Temozolomide
Capsule 140 mg
Oral
Temodal
627.72

12
Temozolomide
Capsule 140 mg
Oral
Temizole 140
627.72

13
Temozolomide
Capsule 20 mg
Oral
Astromide
106.25

14
Temozolomide
Capsule 20 mg
Oral
Temizole 20
106.25

15
Temozolomide
Capsule 20 mg
Oral
Orion Temozolomide
106.25

16
Temozolomide
Capsule 20 mg
Oral
Temodal
106.25

17
Temozolomide
Capsule 250 mg
Oral
Astromide
1081.44

18
Temozolomide
Capsule 250 mg
Oral
Temodal
1081.44

19
Temozolomide
Capsule 250 mg
Oral
Temizole 250
1081.44

20
Temozolomide
Capsule 250 mg
Oral
Orion Temozolomide
1081.44

21
Temozolomide
Capsule 5 mg
Oral
Temizole 5
36.14

22
Temozolomide
Capsule 5 mg
Oral
Astromide
36.14

23
Temozolomide
Capsule 5 mg
Oral
Orion Temozolomide
36.14

24
Temozolomide
Capsule 5 mg
Oral
Temodal
36.14

 
 
 
 
 
 
 
 
 
 
 
Schedule 2              
Brands of pharmaceutical items – unadjusted price reduction is less than 10%
 
Column 1
Column 2
Column 3

Item
Brand of Pharmaceutical Item
Weighted average disclosed price

 
Listed Drug
Form
Manner of administration
Brand
 

1
Dexamethasone
Eye drops 1 mg per mL, 5 mL
Application to the eye
Maxidex
3.38

2
Dexamethasone
Tablet 4 mg
Oral
Dexmethsone
4.45

3
Dexamethasone
Tablet 500 micrograms
Oral
Dexmethsone
1.79

Note
1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.comlaw.gov.au.
Read Entire Law on www.comlaw.gov.au